Market News AIOpen the app

Radiopharm Theranostics shared early results from its Phase 2b study of RAD101 and got FDA Fast Track approval.

TrialRead the original at globenewswire.com
Good for RADX

Radiopharm's 32-person study had no comparison group, and the report gives no accuracy results. FDA Fast Track status and Siemens' role in making and distributing RAD101 support the planned Phase 3 trial, moving development forward.

RADX · Radiopharm Theranostics

AI read · Good for RADX

The AI's read

Fast Track status is not FDA approval, but it marks a step in RAD101's development. Siemens' manufacturing and distribution role supports the planned U.S. Phase 3 trial. The report gives no accuracy results, so it does not show how well the scan works. The development steps still favor Radiopharm.

Get alerts for RADX

Follow Radiopharm Theranostics (RADX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RADX
Free on the App Store and Google Play, or on the web.